Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Cohance Lifesciences Ltd (COHANCE)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543064 NSE: COHANCE Pharmaceuticals & Drugs | Small Cap | Cohance Lifesciences Share Price
₹456.55 -3.60 (-0.78%)
As on 04-Sep'26 16:59
Cohance Lifesciences Ltd (COHANCE)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543064 NSE: COHANCE Pharmaceuticals & Drugs | Small Cap | Cohance Lifesciences Share Price
₹456.55 -3.60 (-0.78%)
As on 04-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹17,467 Cr.
Current Price
₹456.6
52-Week Low / High
₹268 / 1,038
TTM EPS
₹2.8
TTM Sales
₹2,142 Cr.
Book Value per Share
₹100.6
P/E Ratio
164.43
Higher than its 5-year historical median
Industry PE
54.1
Price to Book (P/B)
4.54
Lower than its 5-year historical median
Price to Sales (P/S)
8.16
Lower than its 5-year historical median
EV/EBITDA
50.47
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
4.02%
Underperforms industry median
Return on Capital Employed (ROCE)
6.12%
Underperforms industry median
Return on Assets (ROA)
2.68%
Operating Profit Margin
19%
Net Profit Margin
6.62%
Gross Profit Margin
18.7%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-13.03%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-46.43%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
-69%
Asset Quality
Promoter Holding
57.49%
Pledged shares (%) of Promoter's holding (%)
94.56%
Reserves
₹3,811 Cr.
Equity
₹38.3 Cr.
Face Value
₹1
All Time Low / High
₹87.05 / 1359.00
Check Before You Invest
Quality
Very GoodValuation
UndervaluedCheck Valuation charts
Price Trend
Semi Strong
Is Cohance Lifesciences Ltd a good quality company?
Cohance Lifesciences Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Cohance Lifesciences Ltd performance compare with that of its Peers?
Revenue growth of Cohance Lifesciences Ltd vs industry peers?
Cohance Lifesciences Ltd revenue CAGR is 17.57%, compared to the industry median CAGR of 5.76%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Cohance Lifesciences Ltd?
Promoters hold 57.49% of the Cohance Lifesciences Ltd, with 94.56% of their stake pledged, indicating high pledge risk.
Stock return of Cohance Lifesciences Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of -2.74% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Cohance Lifesciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0% | 0% | 23.9% | 50.2% | 40.8% | 45.9% | 33.4% | 21.2% | 22.8% | 6.1% | - |
| Value Creation Index ⓘ | NA | NA | 0.8 | 2.7 | 2.0 | 2.4 | 1.5 | 0.6 | 1.0 | -0.6 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 0 | 0 | 378 | 834 | 1,010 | 1,320 | 1,340 | 1,051 | 2,609 | 2,269 | 2,142 |
| Sales YoY Gr. | - | NA | NA | 120.7% | 21.1% | 30.8% | 1.5% | -21.6% | 148.1% | -13% | - |
| Adj EPS ⓘ | 0 | 0 | 0 | 12 | 13.9 | 15.3 | 15.1 | 10.3 | 19.1 | 5 | 2.8 |
| YoY Gr. | - | NA | NA | NA | 15.9% | 10.5% | -1.2% | -31.7% | 84.4% | -73.6% | - |
| BVPS (₹) ⓘ | 0 | 0 | 0 | 33.2 | 46.4 | 60 | 68.2 | 80.5 | 140.1 | 101.8 | 100.6 |
| Adj Net Profit ⓘ | 0 | 0 | 111 | 305 | 353 | 390 | 385 | 263 | 485 | 193 | 106 |
| Cash Flow from Ops. ⓘ | 0 | 0 | 50.4 | 407 | 383 | 330 | 457 | 358 | 673 | 368 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 1.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.1 | 0.4 | 0.5 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 17.6% | 19.2% | -13% | ||||
| Adj EPS ⓘ | NA | -18.4% | -30.7% | -73.6% | ||||
| BVPSⓘ | NA | 17% | 14.3% | -27.4% | ||||
| Share Price | - | -2.7% | -4% | -50.5% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0 | 0 | 18.8 | 42.5 | 34.9 | 28.8 | 23.6 | 13.9 | 17 | 5.1 | 2.8 |
| Op. Profit Mgn % ⓘ | 0 | 0 | 46.1 | 46.2 | 43.9 | 44.1 | 42.8 | 38.6 | 30.7 | 19.1 | 14.8 |
| Net Profit Mgn % ⓘ | 0 | 0 | 29.4 | 36.6 | 35 | 29.6 | 28.8 | 25 | 18.5 | 7.2 | 5 |
| Debt to Equity ⓘ | 0 | 0 | 0.1 | 0.2 | 0.1 | 0.1 | 0 | 0 | 0.1 | 0 | - |
| Working Cap Days ⓘ | 0 | 0 | 0 | 196 | 175 | 172 | 195 | 213 | 141 | 251 | 139 |
| Cash Conv. Cycle ⓘ | 0 | 0 | 0 | 81 | 57 | 69 | 89 | 104 | 80 | 145 | 90 |
Valuation of Cohance Lifesciences - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 94.56 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 378 | 834 | 1,010 | 1,320 | 1,340 | 1,051 | 2,609 | 2,269 |
| Operating Expenses ⓘ + | 206 | 449 | 567 | 739 | 766 | 646 | 1,811 | 1,842 |
| Operating Profit ⓘ | 172 | 385 | 443 | 582 | 574 | 406 | 797 | 427 |
| Operating Profit Margin (%) | 45.4% | 46.1% | 43.9% | 44.1% | 42.8% | 38.6% | 30.6% | 18.8% |
| Other Income ⓘ + | 1 | 18 | 14 | 92 | 46 | 62 | 69 | 34 |
| Interest ⓘ | 3 | 23 | 12 | 9 | 13 | 7 | 41 | 37 |
| Depreciation ⓘ | 11 | 24 | 32 | 39 | 48 | 55 | 167 | 187 |
| Profit Before Tax ⓘ | 158 | 405 | 468 | 668 | 560 | 406 | 643 | 207 |
| Tax ⓘ | 49 | 88 | 105 | 214 | 148 | 105 | 158 | 57 |
| Profit After Tax | 109 | 317 | 362 | 454 | 411 | 300 | 484 | 150 |
| PAT Margin (%) | 28.9% | 38.0% | 35.9% | 34.4% | 30.7% | 28.6% | 18.6% | 6.6% |
| Adjusted EPS (₹) | 0.0 | 12.5 | 14.2 | 17.8 | 16.2 | 11.8 | 19.1 | 4.7 |
| Dividend Payout Ratio (%) | 0% | 20.10% | 14.10% | 28.10% | 37.10% | 0% | 0% | 0% |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 578 | 845 | 1,181 | 1,527 | 1,735 | 2,049 | 3,567 | 3,893 | |||
| Debt + | 83 | 185 | 141 | 96 | 69 | 39 | 200 | 125 | |||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 144 | 123 | |||
| Trade Payables | 54 | 71 | 83 | 106 | 70 | 42 | 268 | 285 | |||
| Others Liabilities ⓘ | 102 | 191 | 171 | 238 | 236 | 124 | 1,300 | 1,302 | |||
| Total Liabilities ⓘ | 816 | 1,292 | 1,576 | 1,967 | 2,110 | 2,254 | 5,480 | 5,727 | |||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 271 | 357 | 441 | 534 | 663 | 670 | 3,107 | 3,369 | |||
| CWIP ⓘ | 111 | 102 | 96 | 30 | 165 | 179 | 334 | 178 | |||
| Investments ⓘ | 7 | 338 | 542 | 598 | 536 | 904 | 337 | 529 | |||
| Inventories | 157 | 175 | 201 | 283 | 313 | 231 | 467 | 562 | |||
| Trade Receivables | 148 | 117 | 102 | 236 | 111 | 134 | 772 | 681 | |||
| Cash Equivalents | 13 | 14 | 10 | 47 | 68 | 51 | 102 | 60 | |||
| Others Assets ⓘ | 109 | 190 | 184 | 237 | 254 | 86 | 360 | 349 | |||
| Total Assets ⓘ | 816 | 1,292 | 1,576 | 1,967 | 2,110 | 2,254 | 5,480 | 5,727 | |||
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 50 | 407 | 383 | 330 | 457 | 385 | 673 | 368 |
| Cash Flow From Investing Activity ⓘ + | -65 | -413 | -311 | -136 | -195 | -362 | -390 | -255 |
| Cash Flow From Financing Activity ⓘ + | 26 | 7 | -76 | -156 | -242 | -40 | -327 | -165 |
| Net Cash Flow ⓘ | 11 | 1 | -5 | 37 | 20 | -18 | -44 | -51 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 18.92 | 44.58 | 35.78 | 33.52 | 25.21 | 15.87 | 17.25 | 4.02 | ||
| ROCE (%) | 23.87 | 50.21 | 40.76 | 45.92 | 33.41 | 21.22 | 22.8 | 6.12 | ||
| Asset Turnover Ratio | 0.46 | 0.79 | 0.7 | 0.75 | 0.66 | 0.48 | 0.67 | 0.4 | ||
| PAT to CFO Conversion(x) | 0.46 | 1.28 | 1.06 | 0.73 | 1.11 | 1.28 | 1.39 | 2.45 | ||
| Working Capital Days | ||||||||||
| Receivable Days | 142.50 | 57.90 | 39.70 | 46.80 | 47.30 | 42.50 | 63.40 | 116.90 | ||
| Inventory Days | 151.80 | 72.70 | 68 | 66.90 | 81.10 | 94.40 | 48.90 | 82.80 | ||
| Payable Days | 192.70 | 101 | 94.40 | 87.50 | 79.70 | 65.80 | 69.70 | 153.60 | ||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Cohance Lifesciences Ltd FAQs
The current trading price of Cohance Lifesciences on 04-Sep-2026 16:59 is ₹456.6.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Sep-2026 the market cap of Cohance Lifesciences stood at ₹17,467.5 Cr
The latest P/E ratio of Cohance Lifesciences as of 03-Sep-2026 is 98.38.
The latest P/B ratio of Cohance Lifesciences as of 03-Sep-2026 is 3.91.
The 52-week high of Cohance Lifesciences is ₹1,038 and the 52-week low is ₹267.9.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Cohance Lifesciences is ₹1,907 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Cohance Lifesciences Ltd is a good quality company.
The key valuation ratios of Cohance Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Cohance Lifesciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Cohance Lifesciences Ltd
Headquartered in Hyderabad, Cohance Lifesciences is a global, innovation-driven CDMO platform specialising in high-value, end-to-end solutions across the full spectrum of a molecule’s lifecycle - from early-stage development to large-scale commercialisation - with a marquee Customer Base across Pharmaceuticals and Specialty Chemicals.
With a focus on agility, innovation and global scalability, Cohance Lifesciences is reshaping the landscape of pharmaceutical manufacturing and development. The company collaborates with its customers to enhance their molecules and products, enabling them to deliver innovative solutions to their patients and consumers.
Business area of the company
The company is a fully integrated global CDMO, partnering with leading innovators across the entire product lifecycle- from route scouting and early development to commercial manufacturing. With advanced capabilities in oligonucleotides, bioconjugation and complex small molecules, it addresses some of the most challenging chemistries in the industry.
Business verticals of the company
- Pharma CDMO
- Specialty Chemicals
- API+
Achievements
Achieved B-rating 2024 disclosure both in Climate Change & Water Security.
Social Accountability SA8000.
Silver in Ecovadis Sustainability Assessment.
Pharmaceutical Supply Chain Initiative (PSCI) Supplier Partner- 2025.
British Safety Council’s International Safety Awards (ISA) 2025.
All facilities are certified with ISO 14001, ISO 45001.
Milestones
- 2020: The foundation was laid with the inclusion of RA Chem Pharma, known for its strong footprint in APIs, intermediates, and finished dosage formulations, setting the tone for a platform focused on quality and scientific depth.
- 2021: With the addition of ZCL Chemicals, the platform expanded its capability in complex intermediates, enhancing its ability to serve global pharmaceutical innovators.
- 2022: The journey progressed with Avra, bringing expertise in high-complexity chemistry and ADC payloads – positioning the platform to support next-generation therapeutics.
- 2023: Suven Pharmaceuticals merges with Cohance - Suven Pharmaceuticals, with its rich heritage in CRAMS and custom synthesis, joined hands with the growing platform. This marked a pivotal point where the vision of Cohance – a differentiated, technology-led CDMO platform – began to take shape.
- 2024: Expanding into next-gen therapeutic platforms - While the Cohance–Suven integration was underway, the platform advanced further with Sapala Organics (bringing oligonucleotide capabilities) and NJ Bio (offering end-to-end integrated ADC services), broadening scientific reach in novel modalities.
- 2025: Cohance Lifesciences announced a strategic investment of $10 million to expand cGMP bioconjugation capabilities at its U.S based subsidiary, NJ Bio.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
